Sakakibara T, Hintze T H, Nasjletti A
Department of Physiology, New York Medical College, Valhalla 10595, USA.
Am J Physiol. 1998 Jan;274(1):R120-5. doi: 10.1152/ajpregu.1998.274.1.R120.
We studied the determinants of kinin release into the venous effluent of rat hindquarters perfused with Krebs bicarbonate buffer. Kinin release in preparations perfused with control media (14.6 +/- 2.5-20.7 +/- 6.7 pg/15 min) was surpassed by that in preparations perfused with media containing kininase inhibitors (243 +/- 53 to 276 +/- 78 pg/15 min). Kinin release increased when purified kininogen (from 242 +/- 43 to 3,365 +/- 725 pg/15 min) or kallikrein (from 270 +/- 49 to 30,649 +/- 8,040 pg/15 min) was added to the perfusate. Conversely, kinin release fell when the kallikrein inhibitor aprotinin (from 272 +/- 58 to 122 +/- 27 pg/15 min) or soybean trypsin inhibitor (from 273 +/- 52 to 195 +/- 25 pg/15 min) was added. Both basal and kininogen-induced kinin release were attenuated in preparations perfused with media containing cycloheximide, a protein synthesis inhibitor, but kallikrein-induced kinin release was not. These data suggest that kinin release from perfused rat hindquarters reflects the activity of both the kinin-degrading and kinin-generating pathways and that the latter is sustained by a kallikrein manufactured de novo and by preexistent kininogen(s).
我们研究了缓激肽释放到用 Krebs 碳酸氢盐缓冲液灌注的大鼠后肢静脉流出液中的决定因素。用对照介质灌注的制剂中的缓激肽释放量(14.6±2.5 - 20.7±6.7 pg/15 分钟)低于用含有激肽酶抑制剂的介质灌注的制剂中的缓激肽释放量(243±53 至 276±78 pg/15 分钟)。当向灌注液中添加纯化的激肽原(从 242±43 至 3365±725 pg/15 分钟)或激肽释放酶(从 270±49 至 30649±8040 pg/15 分钟)时,缓激肽释放增加。相反,当添加激肽释放酶抑制剂抑肽酶(从 272±58 至 122±27 pg/15 分钟)或大豆胰蛋白酶抑制剂(从 273±52 至 195±25 pg/15 分钟)时,缓激肽释放减少。在用含有蛋白质合成抑制剂环己酰亚胺的介质灌注的制剂中,基础和激肽原诱导的缓激肽释放均减弱,但激肽释放酶诱导的缓激肽释放未减弱。这些数据表明,从灌注的大鼠后肢释放缓激肽反映了缓激肽降解途径和缓激肽生成途径的活性,并且后者由新合成的激肽释放酶和预先存在的激肽原维持。